London · Delayed Price · Currency is GBP · Price in USD AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of GBP 1.66 million. The enterprise value is 1.60 million.
| Market Cap | 1.66M |
| Enterprise Value | 1.60M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 2.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +102.28% |
| Shares Change (QoQ) | +175.71% |
| Owned by Insiders (%) | 3.82% |
| Owned by Institutions (%) | 4.98% |
| Float | 2.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.88 |
| PB Ratio | -0.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.14 |
| EV / Sales | 19.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64
| Current Ratio | 0.64 |
| Quick Ratio | 0.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -95.42% |
| Return on Invested Capital (ROIC) | -707.41% |
| Return on Capital Employed (ROCE) | -1,003.93% |
| Weighted Average Cost of Capital (WACC) | 14.96% |
| Revenue Per Employee | 3,787 |
| Profits Per Employee | -532,593 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.59% in the last 52 weeks. The beta is 1.24, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -94.59% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 8.07 |
| Relative Strength Index (RSI) | 33.64 |
| Average Volume (20 Days) | 39,631 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.26 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of GBP 83,321 and -11.72 million in losses. Loss per share was -11.08.
| Revenue | 83,321 |
| Gross Profit | 12,647 |
| Operating Income | -10.84M |
| Pretax Income | -11.72M |
| Net Income | -11.72M |
| EBITDA | -10.67M |
| EBIT | -10.84M |
| Loss Per Share | -11.08 |
Balance Sheet
The company has 1.79 million in cash and 1.74 million in debt, with a net cash position of 52,820.
| Cash & Cash Equivalents | 1.79M |
| Total Debt | 1.74M |
| Net Cash | 52,820 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -4.52M |
| Book Value Per Share | -1.63 |
| Working Capital | -1.09M |
Cash Flow
| Operating Cash Flow | -9.62M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 15.18% |
| Operating Margin | -13,006.29% |
| Pretax Margin | -14,062.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.28% |
| Shareholder Yield | -102.28% |
| Earnings Yield | -707.43% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001 |
Scores
AIM ImmunoTech has an Altman Z-Score of -119.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -119.82 |
| Piotroski F-Score | 2 |